You are viewing the site in preview mode
Skip to main content
|
Clinical characteristics
|
Total (n = 47)
|
|---|
|
Age, years
|
|
< 70
|
37 (79%)
|
|
≥ 70
|
10 (21%)
|
|
Gender
|
|
Male
|
38 (81%)
|
|
Female
|
9 (19%)
|
|
ECOG PS
|
|
0
|
12 (25%)
|
|
1
|
28 (60%)
|
|
2
|
7 (15%)
|
|
Disease status
|
|
Primary metastatic
|
36 (77%)
|
|
Recurrent
|
11 (23%)
|
|
Histology
|
|
Well or moderately differentiated
|
21 (45%)
|
|
Poorly differentiated
|
18 (38%)
|
|
Signet ring cell
|
4 (9%)
|
|
Combined, others
|
4 (9%)
|
|
HER2 status
|
|
IHC 3+
|
40 (85%)
|
|
IHC 2+ with SISH +
|
7 (15%)
|
|
Liver metastasis
|
|
No
|
23 (49%)
|
|
Yes
|
24 (51%)
|
|
Peritoneal metastasis
|
|
No
|
32 (68%)
|
|
Yes
|
15 (32%)
|
|
Amount of ascites
|
|
No
|
26 (55%)
|
|
Small or moderate
|
16 (34%)
|
|
Massive
|
5 (11%)
|
|
Surgical resection
|
|
No
|
38 (81%)
|
|
Yesa
|
9 (19%)
|
- ECOG Eastern Cooperative Oncology Group, PS performance status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, SISH silver-enhanced in situ hybridization
- aincluding 6 patients who underwent surgery after chemotherapy
